There are currently 96 clinical trials in Chandler, Arizona looking for participants to engage in research studies. Trials are conducted at various facilities, including GSK Investigational Site, Chandler Regional Medical Center, Arizona Eye Center and Ironwood Cancer and Research Centers. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.
NCT05084638
Recruiting
This study will evaluate the impact of ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) participants that are very early in the course of their disease using clinical and magnetic resonance imaging (MRI) outcomes. The study will also assess changes in disease using monitoring techniques including digital biometric device use, biomarker analysis and non-conventional MRI. Select outcomes in the ofatumumab treated group will be compared to a group of Healthy participants to determine if... Read More
Gender:
All
Ages:
Between 18 years and 35 years
Trial Updated:
02/01/2024
Locations: Novartis Investigative Site, Chandler, Arizona
Conditions: Relapse Remitting Multiple Sclerosis
Register for Updates
An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)
NCT04950764
Recruiting
The Effect of Hepatic Impairment on The Pharmacokinetics of Seladelpar: An Open-Label Study Following Oral Dosing of Seladelpar to Subjects with Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
01/26/2024
Locations: The Institute of Liver Health dba Arizona Liver Health, Chandler, Arizona
Conditions: Primary Biliary Cholangitis, Compensated Cirrhosis, Hepatic Impairment
Register for Updates
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728
Recruiting
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
Gender:
All
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: The Institute For Liver Health - Chandler, Chandler, Arizona
Conditions: NASH - Nonalcoholic Steatohepatitis
Register for Updates
Phase 2b Study of ALTO-100 in MDD
NCT05712187
Recruiting
The purpose of this study is to determine efficacy differences between ALTO-100 and placebo, used either as monotherapy or adjunctively to an antidepressant, related to patient characteristics.
Gender:
All
Ages:
Between 18 years and 64 years
Trial Updated:
01/10/2024
Locations: Site 136, Chandler, Arizona
Conditions: Major Depressive Disorder
Register for Updates
A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH)
NCT04880031
Recruiting
This is a safety study to evaluate BOS-580 administered subcutaneously over 12 weeks in Part A or 24 weeks in Part B.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
01/04/2024
Locations: Arizona Liver Health, Chandler, Arizona
Conditions: Nonalcoholic Steatohepatitis (NASH)
Register for Updates
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
NCT05064553
Recruiting
The primary objective is to assess overall sensitivity and specificity of Oncoguard™ Liver for hepatocellular cancer (HCC) detection in a surveillance population.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/28/2023
Locations: Arizona Health Research, Chandler, Arizona
Conditions: Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis, Liver Cancer
Register for Updates
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH.
NCT05864391
Recruiting
The purpose of this study is to measure the safety, tolerability, and PK (measurement of drug activity in the body over time) of AZD7503 injected subcutaneously, and compared to placebo, in participants with suspected NASH, a type of liver disease.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
12/11/2023
Locations: Research Site, Chandler, Arizona
Conditions: Steatohepatitis
Register for Updates
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
NCT04223856
Recruiting
This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together to treat patients with urothelial cancer. The study will compare these drugs to other drugs that are usually used to treat this cancer (standard of care). The patients in this study will have cancer that has spread from their urinary system to other parts of their body.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/05/2023
Locations: Ironwood Cancer & Research Centers - Chandler, Chandler, Arizona
Conditions: Urothelial Cancer
Register for Updates
Clinical Validation of the RENISCHEM L-FABP POC Assay
NCT04864847
Recruiting
This study will involve measurement of levels of a novel urinary biomarker of renal ischemia, L-FABP. The purpose of the study is to perform a clinical validation of the ability of L-FABP measurements in urine using the RENISCHEM L-FABP POC Test to predict the development of AKI within 2 days following cardiac and vascular catheterization procedures involving exposure to radiocontrast media.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/01/2023
Locations: Chandler Regional Medical Center, Chandler, Arizona
Conditions: Acute Kidney Injury, Contrast-induced Nephropathy
Register for Updates
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
NCT04951219
Recruiting
A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resmetirom (MGL-3196)
Gender:
All
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: Arizona Liver Health - Chandler, Chandler, Arizona +1 locations
Conditions: Non-Alcoholic Fatty Liver Disease
Register for Updates
Genetic Risk Stratification for Primary Prevention of CAD in Men and Pre & Post-menopausal Women
NCT05169840
Recruiting
The investigators propose to genotype males and females at age 40 years and older, who are asymptomatic and without known heart disease (N=2000). DNA from a blood sample will be genotyped for millions of genetic risk variants for CAD by Baylor College of Medicine Human Genome Sequencing Center Clinical Laboratory (HGSC-CL) in a CLIA-approved laboratory. The overall objective after 2 years is to determine if genetic screening for risk of CAD in asymptomatic men and women has the discriminatory p... Read More
Gender:
All
Ages:
Between 40 years and 60 years
Trial Updated:
11/22/2023
Locations: Chandler Regional Medical Center, Chandler, Arizona
Conditions: Coronary Artery Disease, Genetic Predisposition to Disease
Register for Updates
Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients
NCT05586971
Recruiting
The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
10/17/2023
Locations: Arizona Research Clinic, PLLC, Chandler, Arizona
Conditions: Gout, Hyperuricemia, Gout Flare, Tophi
Register for Updates